Combination therapy with Olaratumab/ doxorubicin in advanced or metastatic soft tissue sarcoma - a single-Centre experience

The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA).